Cerebrolysin: what it is, and what the evidence actually shows

Cerebrolysin turns up in nootropic forums as a kind of injectable brain tonic, and in some countries it sits on hospital shelves as a stroke and dementia drug. Both framings deserve a careful, skeptical read, because what Cerebrolysin actually is — and what the best evidence says about whether it works — are two very different conversations. Here is the straight version of each.

What it actually is

Cerebrolysin is not a single molecule. It is a mixture of low-molecular-weight neuropeptides and free amino acids produced by the enzymatic breakdown of purified porcine (pig) brain tissue, administered by injection or intravenous infusion.^[1] That biological origin is worth pausing on: it is a defined-but-complex protein-derived preparation, not a synthetic peptide with a single sequence and a clean dose-response. It has been used for decades in Russia, Eastern Europe, China and other Asian and post-Soviet countries for acute ischaemic stroke; elsewhere it is also promoted for vascular dementia and traumatic brain injury.^[1] It is not FDA-approved in the United States, and it is not registered across most of the European Union — a regulatory gap that itself tells you the evidence has not cleared the bar those agencies require.

The proposed mechanism

The marketing rationale is “neurotrophic.” The idea is that Cerebrolysin's peptide fragments mimic the action of endogenous neurotrophic factors — the signaling proteins that support neuron survival, plasticity and repair — thereby protecting brain tissue after an insult and encouraging recovery.^[1] It is a plausible-sounding story, and it is the same family of logic that animates interest in growth-factor-adjacent peptides like dihexa. But a plausible mechanism is a hypothesis, not a result. The relevant question is not whether the theory is elegant; it is whether randomized trials show that giving Cerebrolysin changes outcomes that matter. That is where the story gets far less flattering.

Acute ischaemic stroke: the Cochrane anchor

Stroke is Cerebrolysin's flagship indication, so the Cochrane systematic review is the fairest place to judge it. Pooling the randomized evidence, Cochrane concluded — with moderate-certainty evidence — that Cerebrolysin probably has no beneficial effect on preventing all-cause death after acute ischaemic stroke, and probably makes little or no difference to the total number of people experiencing serious adverse events.^[1] More pointedly, the same review flagged a potential increase in non-fatal serious adverse events with Cerebrolysin.^[1] In other words, the best synthesis of the trial data does not show it helps, and raises a safety question rather than resolving one.

The largest individual trial reinforces that picture. CASTA, a double-blind, placebo-controlled study of 1,070 patients across Asia, found no significant difference between Cerebrolysin and placebo on its confirmatory endpoint; only a post-hoc subgroup of more severe strokes showed a non-definitive trend in its favor.^[3] Post-hoc subgroup trends are hypothesis-generating, not proof — they are exactly the kind of finding that later, properly powered trials so often fail to reproduce.

The one bright-ish spot is CARS, a smaller randomized trial in early stroke rehabilitation, which reported a benefit on arm-motor function and global outcome at 90 days.^[2] It is a real, positive result — but it measured functional recovery in a rehabilitation setting rather than death or disability, it was smaller, and it does not overturn the pooled conclusion that Cerebrolysin does not improve the hardest stroke outcomes.

Vascular dementia: even thinner

For vascular dementia, the Cochrane review is blunt about the quality of what exists: six small randomized trials totaling under 600 participants, conducted mostly in China, Russia and Romania, and — where funding was disclosed — supported by the pharmaceutical industry. Pooling the cognitive scores produced a modest apparent benefit, but the reviewers graded it as very low-quality evidence, meaning the true effect could be substantially different or absent.^[4] A concentration of positive results in a handful of regions, funded by the manufacturer, on small trials, with low-certainty grading, is precisely the pattern that should make a careful reader cautious rather than convinced.

The “nootropic” use in healthy people

None of the evidence above involves healthy adults seeking a cognitive edge. The clinical trials enrolled patients with stroke or dementia, and even there the results are weak or null. There is no good evidence that Cerebrolysin enhances memory, focus or cognition in healthy people — that use is entirely off-label and untested. The same honest standard applies to the peptide nootropics it is often mentioned alongside, such as Semax and Selank, whose human data are similarly limited and regionally concentrated, and to longevity compounds like NAD precursors where enthusiasm has repeatedly outrun the trial evidence. Extrapolating from a porcine-brain mixture tested in sick patients to a performance boost in well people is not supported by data.

The honest bottom line

Cerebrolysin is a decades-old, porcine-brain-derived peptide preparation with a plausible neurotrophic story and a genuinely weak evidence base. For its flagship indication, acute ischaemic stroke, the pooled randomized data show no benefit on death and hint at added harm.^[1] For vascular dementia, the evidence is very low quality and geographically narrow.^[4] It is not approved in the US or most of the EU, and there is no basis for using it as a cognitive enhancer in healthy people. This is a case where the marketing, the anecdotes and the mechanism all point one way and the best evidence points another — and when they disagree, the evidence wins.